论文部分内容阅读
目的对安博维与依伦平治疗原发性高血压进行比较研究。方法将132例入选血压90 mm Hg(1 mm Hg=0.133 kPa)≤舒张压(DBP)<110 mm Hg,且收缩压(SBP)<180 mm Hg的来院治疗的患者分成两组,一组(n=62)加用安博维(厄贝沙坦)150 mg,每日1次;另一组(n=70)加用依伦平(厄贝沙坦150 mg+氢氯噻嗪12.5 mg)片,每日1次,观察8周,对两组血压、心率、血压达标率、降压有效率、不良反应进行比较。结果两组在分组后1周SBP、DBP和脉压(PP)均开始下降,依伦平组在分组后1周,安博维在分组后2周SBP、DBP和PP下降幅度较分组时差异有统计学意义(P<0.01);两组间SBP、DBP和PP在整个观察期内相比,同时间随访观察值、心率(HR)差异无统计学意义。结论安博维与依伦平在治疗原发性高血压方面的疗效、安全性和耐受性方面均较好,相比之下依伦平起效更快,降压有效率、达标率更高,是原发性高血压治疗的理想用药。
Objective To compare the effects of ambroxol and eplerenin on essential hypertension. Methods 132 hospitalized patients with a blood pressure of 90 mm Hg (1 mm Hg = 0.133 kPa) ≤ diastolic blood pressure (DBP) <110 mm Hg and SBP <180 mm Hg were divided into two groups, one group ( n = 62) plus anbovi (irbesartan) 150 mg once daily; the other group (n = 70) plus eruptive (irbesartan 150 mg + hydrochlorothiazide 12.5 mg) tablets daily 1 times, observed for 8 weeks, the two groups of blood pressure, heart rate, blood pressure compliance rate, effective antihypertensive, adverse reactions were compared. Results The SBP, DBP and pulse pressure (PP) of two groups began to decrease at 1 week after treatment. The difference of SBP, DBP, and PP in ambroxol group was statistically significant Statistical significance (P <0.01). There was no significant difference in SBP, DBP and PP between the two groups during the whole observation period and between the same period of follow-up observation and heart rate (HR). Conclusions Ambroix and eriodipine are superior in efficacy, safety and tolerability in the treatment of essential hypertension compared to eupronin, which is more effective and effective in lowering blood pressure and has a higher compliance rate , Is the ideal treatment for essential hypertension.